Skip to main content
Premium Trial:

Request an Annual Quote

Genedrive, FIND Partner on HCV Assay Evaluation Study

NEW YORK (GenomeWeb) – Genedrive announced today that it has partnered with the Foundation for Innovative New Diagnostics (FIND) to begin a study to evaluate the firm's hepatitis C Virus ID Kit.

Genedrive's HCV ID Kit runs on the firm's portable molecular diagnostics platform and is designed for use in low-resource settings, delivering results in 90 minutes. The platform uses PCR amplification and melt curve analysis to rapidly amplify and detect target nucleic acid sequences without the need for nucleic acid isolation.

As part of the agreement, FIND will lead evaluation studies on the firm's assays in Cameroon and Georgia between September 2018 and May 2019. The studies are designed to confirm the assay's accuracy across a variety of genotypes, as well as to assess "usability in the intended market setting," the firm said.

In addition, Genedrive will provide product in-kind to support the study.

"Positive outcomes should further facilitate our commercialization activities in these regions, as well as provid[e] important clinical field data that others look to as they decide to implement Genedrive in their own specific settings," Genedrive CEO David Budd said in a statement.

FIND will integrate the evaluations of the firm's kit as part of its wider HCV diagnostics efforts. The group is the lead partner on a multi-year, multi-country project funded by Unitaid to advance development of simple HCV diagnostic tools.

Earlier this week, FIND signed a memorandum of understanding with Clinical Research Malaysia to develop a new strategy to diagnose HCV in decentralized primary healthcare facilities. Last month, FIND awarded grants to several firms to develop new HCV diagnostics, as well.   

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.